Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

PharmID: pharmacophore identification using Gibbs sampling.

Jun Feng1, Ashish Sanil, S Stanley Young

  • 1National Institute of Statistical Sciences, P.O. Box 14006, Research Triangle Park, North Carolina 27709-4006, USA.

Journal of Chemical Information and Modeling
|May 23, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery.

Clinical cancer research : an official journal of the American Association for Cancer Research·2023
Same author

Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.

NPJ breast cancer·2022
Same author

Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2<sup>+</sup> breast cancer in the adaptively randomized I-SPY2 trial.

Nature communications·2021
Same author

Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer.

NPJ breast cancer·2021
Same author

Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.

Cancer cell·2021
Same author

Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.

JAMA·2020
Same journal

PFASGroups: An Open-Source Framework for Automated Identification, Structural Classification, and Prioritization of Per- and Polyfluoroalkyl Substances.

Journal of chemical information and modeling·2026
Same journal

DeepKbhb: Context-Aware Prediction of Human Lysine β-Hydroxybutyrylation Sites.

Journal of chemical information and modeling·2026
Same journal

HyperDC: A Non-Uniform Hypergraph Framework for Dual- and Higher-Order Drug Combination Recommendation Across Diverse Complex Diseases.

Journal of chemical information and modeling·2026
Same journal

Correction to "AstraMEV (AI-Guided Structural Assembly of Multi-Epitope Vaccines) Against Infectious Bronchitis Virus".

Journal of chemical information and modeling·2026
Same journal

MolPy: A Large Language Model-Friendly Toolkit for Reactive Topology Editing in Polymer Simulations.

Journal of chemical information and modeling·2026
Same journal

Molecular Mechanisms of KIT Receptor Dimerization and Oncogenic Activation Revealed by Multiscale Simulations.

Journal of chemical information and modeling·2026
See all related articles

This study presents a new computational method to identify the 3D pharmacophore of small molecules from bioassay data when protein structures are unavailable. The algorithm accurately predicts binding features and handles multiple binding modes efficiently.

Area of Science:

  • Computational chemistry
  • Drug discovery
  • Structural biology

Background:

  • Protein-ligand binding is a 3D matching problem crucial for drug design.
  • Crystal structures are often unavailable for drug targets, necessitating alternative methods to determine binding interactions.
  • Identifying the pharmacophore (key binding features and their spatial arrangement) is essential for understanding small molecule interactions.

Purpose of the Study:

  • To develop and validate a computational algorithm for inferring pharmacophores from bioassay data.
  • To address the challenge of determining small molecule binding features in the absence of experimental structures.
  • To create a method capable of handling multiple binding modes within a single dataset.

Main Methods:

  • Utilized 3D feature fingerprints and a modified Gibbs sampling approach to align active ligands.

Related Experiment Videos

  • Employed clique detection to map identified features onto molecular conformations.
  • Developed an algorithm to handle and superimpose molecules with multiple distinct binding modes.

    • Main Results:

    • The algorithm successfully identified common superimpositions for multiple test datasets.
    • Predicted pharmacophores closely matched crystal structures and literature data.
    • The method demonstrated efficiency, handling up to 100 compounds and tens of thousands of conformations.
    • Successfully applied to identify multiple binding modes for D2 and D4 ligands.

    Conclusions:

    • The developed algorithm provides a robust and efficient method for pharmacophore elucidation using bioassay data.
    • It accurately predicts key binding features and spatial arrangements, even without protein structural information.
    • The capability to handle multiple binding modes enhances its utility in complex drug discovery scenarios.